The Russian Direct Investment Fund (RDIF), GL Rapha, one of South Korea’s leading biotechnology companies and ISU ABXIS (a division of ISU GROUP) have signed an agreement of the technological transfer and production of Russian vaccine against Sputnik V coronavirus in Korea, RDIF reports.
In February 2021, GL Rapha created a consortium for the production of the Sputnik V vaccine in Korea, which included eight leading pharmaceutical companies.
“Korea is a key partner of the Sputnik V vaccine production. Through an agreement with ISU ABXIS, we anticipate expansion of production capacity for vaccine release in the country. Sputnik V is approved in 60 countries with a population of 3 billion people, and we are actively increasing vaccine production to meet growing global demand, “said Kirill Dmitriev, CEO of the RDIF.
“This is the first agreement between a member of the consortium and RDIF to carry out a technological transfer. We continue to interact with partners and will do everything to master the technologies for the production of the Sputnik V vaccine and its supply as soon as possible, “said Suhyun Jung, head of business development at ISU ABXIS.
The agreement between RDIF, GL Rapha and ISU ABXIS is the first tripartite agreement to implement the technology transfer of the company, which is part of the consortium. As expected, the production of the drug at the ISU ABXIS enterprise in the city of Yongyin will begin in late April.
